anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Give primary attention to re-establishment of a patent airway and institution of assisted or controlled ventilation. Employ supportive measures (including oxygen and vasopressors) in the management of circulatory shock and pulmonary edema accompanying overdose as indicated. Cardiac arrest or arrhythmias may require cardiac massage or defibrillation.

The pure opioid antagonists, naloxone or nalmefene, are specific antidotes to respiratory depression resulting from opioid overdose. Since the duration of reversal is expected to be less than the duration of action of morphine sulfate, carefully monitor the patient until spontaneous respiration is reliably re-established. If the response to opioid antagonists is sub-optimal or only brief in nature, administer additional antagonist as directed by the manufacturer of the product.

Do not administer opioid antagonists in the absence of clinically significant respiratory or circulatory depression secondary to morphine sulfate overdose. Administer such agents cautiously to persons who are known, or suspected to be physically dependent on morphine sulfate. In such cases, an abrupt or complete reversal of opioid effects may precipitate an acute abstinence syndrome.

In an individual physically dependent on opioids, administration of the usual dose of the antagonist will precipitate an acute withdrawal syndrome. The severity of the withdrawal symptoms experienced will depend on the degree of physical dependence and the dose of the antagonist administered. Reserve use of an opioid antagonist for cases where such treatment is clearly needed. If it is necessary to treat serious respiratory depression in the physically dependent patient, initiate administration of the antagonist with care and titrate with smaller than usual doses.
The pain coping skills training will be delivered by physical therapists in eight one-hour sessions by telephone over a 2-month perioperative period. Patients will be taught a variety of skills designed to improve maladaptive pain related thoughts and actions to enhance recovery following arthroplasty.
Group 4 will receive 50 µg Tc99m-tilmanocept radiolabeled with 5 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
Participants will exercise 3 times a week for 6 weeks (18 sessions in total, 45-60 minutes each session) in accompany with a physiotherapist. Since the chosen model for exercise training is clinical pilates exercises, separate patient training will be needed. First 3 weeks planned as Warming Phase, Exercise Phase (first 3 weeks), Cooling Phase; and Second 3 weeks planned as Warming Phase, Exercise Phase (first 3 weeks), Cooling Phase.
The invention discloses a formula for oral administration and external use of Yi medicine for whitening and beautifying, which is prepared from semen Benincasae, bletilla striata and the like, and has the effects of making the face glossy, beautifying and removing black scar. The above materials are ground into fine powder and taken with wine to assist the efficacy of the drugs by dispelling the effects of the wine. The formula can remove chloasma and whiten the face by the principle of regulating qi and activating blood. The oral and external Yi medicine is taken as a precondition of dietetic invigoration, can help human body to invigorate qi and blood, has the functions of conditioning viscera and balancing bodies, and is mainly used for beautifying and nourishing by regulating the channels and collaterals, qi and blood in the bodies. Therefore, the facial mask not only can effectively improve the effect of facial care, but also can play a role in regulating, supplementing and nourishing the body. The whitening and beautifying prescription disclosed by the invention has the advantages that a plurality of components are common Yi-nationality medicines, and the preparation is simple and the effect is good.
4-octyl itaconate (4-OI) is a cell-permeable itaconate derivative with anti-inflammatory and antioxidant properties. However, its therapeutic potential for oxidative stress-induced liver injury remains unknown. This study investigated the hepatoprotective effects and mechanisms of 4-OI against oxidative damage in in vitro and in vivo models. 4-OI attenuated H2O2-induced cytotoxicity, oxidative stress, and mitochondrial dysfunction in L02 and HepG2 cells. Untargeted metabolomics profiling and pathway analysis identified the PI3K/AKT/mTOR and MAPK pathways as key regulators of 4-OI's protective effects. Specifically, 4-OI induced phosphorylation of AKT and ERK1/2, leading to activation of the Nrf2 signaling pathway. Nrf2 upregulated expression of the mitochondrial deacetylase Sirt3, which subsequently alleviated H2O2-induced cell injury. In mice, 4-OI reduced acetaminophen (APAP)-induced liver injury as evidenced by attenuated hepatocellular necrosis and decreased serum liver enzymes. It also elevated hepatic expression of Nrf2, Sirt3, p-AKT and p-ERK1/2. Inhibition of AKT, ERK1/2 or Nrf2 blocked the protective effects of 4-OI in vitro, suggesting its antioxidant activity is mediated by activating the Nrf2/Sirt3 pathway via AKT and ERK1/2 phosphorylation. In summary, 4-OI exerted antioxidant and hepatoprotective effects by activating the Nrf2/Sirt3 signaling pathway through AKT and ERK1/2 phosphorylation, which were elucidated using in vitro and in vivo oxidative stress models. This provides novel insights into the mechanisms of 4-OI against oxidative stress-related liver diseases.
Example systems and methods concern systems and methods for modeling conduction in a volume. In one embodiment, diffusion eigenvalues of a plurality of diffusion tensors are received. The diffusion tensors are associated with an anatomical structure having heterogeneous and anisotropic tissues. In one embodiment, the diffusion eigenvalues of the diffusion tensors are calculated from imaging data. Then one or more conductance ratios of a conductivity tensor are set based, at least in part, on one or more diffusion ratios of a corresponding diffusion tensor. The conductance eigenvalues of a conductivity tensor can then be calculated based, at least in part, on the one or more conductance ratios of the conductivity tensor. A volume-conductor model of the anatomical structure is generated based, at least in part, on the plurality of calculated conductivity tensors.
Participants randomized to the Telehealth-Based Intervention Arm who require referral to ophthalmology will be teamed up with a Patient Navigator who will provide telehealth-based support with scheduling an in-office glaucoma evaluation at either Columbia University Harkness Eye Institute, Harlem Hospital, or their own eye care provider. Participants will also receive telehealth-based support from a Peer Ambassador, who are individuals from the community with glaucoma or other eye diseases who have expressed interest in sharing their experiences. Each referred participant will receive several telehealth-based calls from a Peer Ambassador over 2 years to discuss their understanding of their new ocular diagnosis and encourage adherence to in-office glaucoma evaluation.
The Share plus intervention is a behavioral intervention administered by a certified diabetes education and care specialist (CDCES) using telehealth. Share plus consists of three educational sessions to facilitate dyads' success in data sharing glucose levels. The Share plus intervention has five major components that are delivered using techniques of motivational interviewing: 1) shared appraisal, 2) communication strategies, 3) problem-solving strategies, 4) action planning and, 5) re-evaluating, practicing, and advancing.
Liver ischaemia-reperfusion (IR) during hepatic surgeries can lead to liver cell death via oxidative stress and the activation of immune cells, the release of cytokines, and damage-associated molecular patterns. Ascorbic acid has been shown to confer potential protective effects against IR injury, mainly due to its antioxidant properties. This study evaluated the effect of ascorbic acid infusion at different time points during hepatic IR in rats. Thirty-six male Wistar rats were divided into control and experimental groups that received the same total ascorbic acid dose at three different infusion times: before ischaemia, before reperfusion, or before both ischaemia and reperfusion. All of the animals experienced hepatic IR injury. We measured the hepatic enzymes, cytokines, and portal blood flow. Animals receiving ascorbic acid before both ischaemia and reperfusion had lower liver enzyme levels, reduced inflammation, and better portal venous flow than other animals. Divided doses of ascorbic acid before IR may be beneficial for reducing liver injury associated with IR.
The invention comprises a composition comprising mixtures of oligopeptides of the formula R1-CO-(HN-R-CO-)xR2 wherein R is the residue of a basic a -amino carboxylic acid devoid of its a -amino group and carboxyl group, R1CO is the acyl group of a fatty acid containing at least ten carbon atoms, R2 is a hydroxy, alkoxy, amino, alkylamino, dialkylamino or hydrazino group and x is an integer of from 2 to 20, or of acid addition salts thereof; the preparation thereof by reacting in the presence of an organic solvent an N-carboxy anhydride of the formula <FORM:0984709/C2/1> wherein R0 is the residue of a basic a -amino carboxylic acid devoid of its a -amino and carboxylic groups and the o -amino group of which is protected (e.g. with a benzoyloxycarbonyl, a phthaloyl or a formyl group), with ammonia, an alkylamine, a dialkylamine, hydrazine, or a compound of the formula H2N-R0-CO-R2 acylating the oligopeptide compounds obtained with an acylating agent which introduces the acyl radical of the fatty acid R1COOH, splitting off protecting groups present and, if desired, converting the resulting oligopeptide mixture into acid addition salts thereof.  The product of any stage of the process may be saponified and esterified, or re-esterified and reamidated. The group R is a residue of a D-, L- or DL- basic amino acid, preferably lysine, arginine, ornithine, a ,g -diaminobutyric acid, a ,b -diaminopropionic acid or histidine.  The compositions consist substantially of di- and tri-peptides.  Pharmaceutical compositions having anti-bacterial action comprise the compositions of the invention together with a compatible carrier.  The compositions may be formulated as aqueous solutions, tinctures or salves.
The invention relates to a traditional Chinese medicine cinnabar-ginseng pill for treating pediatric epilepsy. The traditional Chinese medicine cinnabar-ginseng pill is mainly used for solving the problem that the current drugs for treating pediatric epilepsy are poor in treatment effect and have side effects. The traditional Chinese medicine cinnabar-ginseng pill is prepared through the steps of weighing 3-5 parts of ginseng, 3-5 parts of cinnabar and 3-5 parts of clam powder, baking, co-grinding into fine powder, and pilling in the size of parasol tree seeds with pig heart blood. The usage and dosage are as follows: the pill is orally taken 2-3 times every day by 1.5-2.5g every time, and the dosage for children is halved; the pill can be orally taken continuously. The traditional Chinese medicine cinnabar-ginseng pill has the aims and advantages that the total effective rate for pediatric epilepsy treatment is over 95%, and the cure rate is over 80%. The traditional Chinese medicine cinnabar-ginseng pill is free from toxic and side effects.
Chronic cough is a very common entity that affects 9.6% people worldwide. Given the high number of patients with refractory cough, the concept of cough hypersensitivity syndrome (CHS) has emerged. In CHS, afferent sensory nerves may exhibit a modification of activation patterns with facilitation of encoding signals in response to irritating stimuli. Similar patterns with neuropathic pain have been described. Small fiber neuropathy has never been assessed in chronic cough. Interestingly, diabetic patients experienced cough more frequently than healthy subject. We hypothesized that small fiber neuropathy may explain chronic cough is more frequent in diabetic patients.

Within 60 days after inclusion, diabetic patients with and without chronic cough will perform neurophysiological tests such as electromyography, thermotest, QSART (Quantitative Sudomotor Axon Reflex Test and Sudoscan), cardio-vascular tests to study the autonomic nervous system. No risks are expecting with these non-invasive tests. A skin biopsy to evaluate small fiber neuropathy will also be performed.After the neurophysiological tests, a consultation will be scheduled at 6 months. A cough VAS and LCQ will be used to assess cough.
A 21-day low-fat experimental diet. Eucaloric diet to Arm #1 with macronutrient and fatty acid class profiles differing only in type of fat and, thus, the proportion of single fatty acids. A control fat is used to replace dairy fats.
This study is a prospective, non-concurrent, multicenter study to compare the clinical and radiographic outcomes of smooth PEEK, 3D-printed titanium, and Porous PEEK interbody implants when used with cancellous allograft chips with BMA or cellular allograft in subjects who undergo XLIF surgery at one or two levels. To minimize selection bias, all consecutive patients at a given site who meet eligibility requirements will be asked to consent to participate in the study. These patients will present with degenerative conditions in the lumbar spine that are amenable to surgical treatment and will be screened prior to study enrollment. Once enrolled into the study, subjects will undergo their XLIF operation using one of the 3 previously noted interbody implants based on a non-concurrent enrollment schedule. The bone graft material used inside the interbody implant will be randomly assigned between cancellous allograft chips with BMA or cellular allograft prior to surgery based on surgeon investigators' equipoise for the effectiveness of both bone graft materials. Subjects will be followed for 24 months following surgery to determine the number of study subjects that are solidly fused at or before 24 months postoperatively.
Point-of-care ultrasound (POCUS) is an important tool for clinical diagnosis and decision-making in critical and non-critical scenarios. Dyspnea, chest pain, and shock are conditions susceptible to evaluation with ultrasound considering diagnostic accuracy and clinical impact already proven. There is scarce evidence in diagnosis agreement using ultrasound as an extension of physical examination. We aimed to evaluate ED patients in whom POCUS was performed, to analyze agreement between clinical initial diagnosis using ultrasound images and final diagnosis. Furthermore, we analyze failed diagnosis, inconclusive POCUS exams, and discuss details. A cross-sectional analytical study was conducted on adults who visited the emergency department with any of these three chief complaints: dyspnea, chest pain, and shock. All were evaluated with ultrasound at admission. Agreement between initial diagnosis using POCUS and final definite diagnosis was calculated. Failed diagnosis and inconclusive exams were analyzed. A total of 209 patients were analyzed. Populations: mostly males, mean age 64 years old, hypertensive. Agreement on patients with dyspnea and suspicion of acute decompensated heart failure was 0.98; agreement on chest pain suspicion of non-ST acute coronary syndrome was 0.96; agreement on type of shock was 0.90. Among the population, 12 patients had an inconclusive POCUS exam, and 16 patients had a failed diagnosis. The use of POCUS in the emergency department shows almost perfect agreement when compared with the final diagnosis in individuals experiencing acutely decompensated heart failure, acute coronary syndrome, and shock. Prospective studies are needed to evaluate the impact of this tool on mortality and prognosis when there are diagnostic errors.
Provided is a nanoparticulate composite with two layers. One of the layers comprises one or more metals, which are a paramagnetic metal, a ferromagnetic metal, or a superparamagnetic metal. This layer also contains one or more suitable dopants. The other layer comprises one or more metals of gadolinium, manganese (II), and iron (III), in the form of an oxide or a fluoride. This layer may contain one or more lanthanide dopants. The nanoparticulate composite may be used as a contrast agent, in particular in magnetic resonance imaging.
The surgical treatment of glaucoma has been and is still based on filtering surgeries, commonly used for about half a century. The safety and efficacy of these techniques have been well described, as it has also been done for cyclophotocoagulation and valves or tubes, indicated in France mostly for refractory glaucoma. Minimally invasive glaucoma surgeries have emerged in recent decades, increasing the number of therapeutic options, and allowing treatment decisions to be as patient-centered as possible. Most of these techniques have now been studied for more than five years. Since glaucoma is a chronic, progressive optic neuropathy, the sustainability of each surgery's results is essential. The amount of available data concerning long-term efficacy and safety of glaucoma surgeries is increasing, so we have decided to describe it through this review of the literature.
BACKGROUND: The extent to which gender affects outcomes in chronic rhinosinusitis (CRS) is unclear. The objective of this study was to examine differential outcomes between genders following endoscopic sinus surgery (ESS) among CRS patients.
METHODS: PubMed/Ovid, Embase and Cochrane databases were queried. Outcomes included disease burden on imaging and endoscopy, patient-reported outcome measures (PROMs) including the Sinonasal Outcome Test (SNOT-22), revision rates, and olfactory outcomes. Meta-analysis was performed using the Mantel-Haenszel method with random effects model.
RESULTS: Of 4,656 articles screened, 32 (n=103,499) were included for qualitative analysis and four (n=2,602) for meta-analysis. On qualitative analysis, 19 of the 32 studies noted a significant gender difference in post-operative outcomes, with five studies favoring women and 14 favoring men. Nine of 18 studies with PROMs noted a difference between genders, all favoring men. Olfactory outcomes were mixed with studies divided on favoring men vs women. No studies noted significant gender differences of disease burden on imaging or endoscopy. Across four studies included in the meta-analysis, women had higher preoperative and post-operative SNOT-22 scores.
CONCLUSION: Meta-analysis shows that women patients have worse pre and postoperative SNOT-22 scores. Postoperative gender differences are most apparent in studies that examined PROMs. Further research is needed to investigate the underlying causes and to mitigate disparities between genders.
The central hypothesis is that accumulation of ADMA constitutes a major mechanism for the sympathetic overactivity and hypertension in patients with CKD. In this study, the investigators will determine if restoration of NO production with the infusion of L-arginine reduces SNA and blood pressure. On the experimental day, CKD patients will arrive at the laboratory fasted with no morning meds, will refrain from caffeine for 12 hours, and alcohol and physical activity for 24 hours. The collaborating physician Dr. Ashfaq Siddiqui will review subject medications and advise regarding any withholding of medications. If Dr. Siddiqui deems that a medication should not be withheld the investigators will proceed with the patient taking the medication. Prior to any screening/testing, all experimental measurements and procedures will be explained in detail and subjects will provide written, informed consent. A medical health history questionnaire will be filled out. Women of child-bearing age will provide a urine sample for a pregnancy testing prior to any study procedures. The research nurse will place an intravenous catheter in antecubital or hand vein. Subjects will be familiarized with the experimental measures and procedures prior to actual testing. Following this, the subjects will be instrumented with ECG leads, an arterial blood pressure (BP) finger-cuff (Finometer), an arterial BP upper-arm cuff for intermittent absolute BP values, and a strain gauge pneumobelt placed around the abdomen to monitor respiratory excursions. After measuring blood pressure and pulse wave velocity using applanation tonometry, a Doppler ultrasound probe will then be positioned for beat-to-beat measurements of blood velocity and artery diameter and flow-mediated dilation (FMD) will be performed. After this, continuous recording of muscle sympathetic nerve activity (MSNA) will be obtained from the peroneal nerve of the leg, as described below. Following all instrumentation, 25 minutes of resting baseline data (continuous heart rate, MSNA, BP, respiration, and blood flow) will be collected. A blood sample will then be obtained from the intravenous catheter. Next, systemic intravenous infusion of L-arginine, at a dose of 250-350 mg/kg, or saline will be performed for 30 minutes in a randomized order. During each infusion, cardiovascular measurements (heart rate, BP and MSNA) will be recorded continuously and an FMD and cold pressor test performed. The blood draw will be repeated after L-arginine infusion. A 15-minute recovery period will be provided between infusions. Thus, for this study, patients will visit the lab once and the visit will take approximately 5 hours.
Patients receive irinotecan IV over 90 minutes once every 3 weeks. Treatment continues for at least 2 courses in the absence of disease progression or unacceptable toxicity.
Adults

Dose Selection— Quetiapine fumarate tablets should generally be administered with an initial dose of 25 mg twice daily, with increases in total daily dose of 25 mg to 50 mg divided in two or three doses on the second and third day, as tolerated, to a total dose range of 300 mg to 400 mg daily by the fourth day. Further dosage adjustments, if indicated, should generally occur at intervals of not less than 2 days, as steady-state for quetiapine fumarate tablets would not be achieved for approximately 1 to 2 days in the typical patient. When dosage adjustments are necessary, dose increments/decrements of 25 mg to 50 mg divided twice daily are recommended. Most efficacy data with quetiapine fumarate tablets were obtained using three times daily dosing regimens, but in one controlled trial 225 mg given twice per day was also effective.

Efficacy in schizophrenia was demonstrated in a dose range of 150 mg/day to 750 mg/day in the clinical trials supporting the effectiveness of quetiapine fumarate tablets. In a dose response study, doses above 300 mg/day were not demonstrated to be more efficacious than the 300 mg/day dose. In other studies, however, doses in the range of 400 mg/day to 500 mg/day appeared to be needed. The safety of doses above 800 mg/day has not been evaluated in clinical trials.

Maintenance Treatment— The effectiveness of quetiapine fumarate tablets for longer than 6 weeks has not been evaluated in controlled clinical trials. While there is no body of evidence available to answer the question of how long the patient treated with quetiapine fumarate tablets should be maintained, it is generally recommended that responding patients be continued beyond the acute response, but at the lowest dose needed to maintain remission. Patients should be periodically reassessed to determine the need for maintenance treatment. 

Adolescents (13 to 17 years)

Pediatric dosing information in patients (13 to 17 years of age) with schizophrenia is approved for AstraZeneca Pharmaceuticals LP’s quetiapine fumarate drug product labeling. However, due to AstraZeneca Pharmaceuticals LP’s marketing exclusivity rights; this drug product is not labeled for such use in those adolescent patients.